“Global Clinical Trial Supply and Logistics market for pharma set to grow to $26bn by 2024” says new Visiongain report

18 April 2019
Pharma

Visiongain has launched a new pharma report Clinical Trial Supply and Logistics Market for Pharma 2019-2029: Clinical Trial Manufacturing, Clinical Trial Logistics and Distributions, Clinical Trial Supply Chain Management, Clinical Trial Packaging, Clinical Trial Cold Chain Logistics.

Demands for increasingly complex and expensive clinical trials have led drug developers to look to external service providers to source clinical trial materials and deliver them to investigator sites. Demand for biological and orphan drugs will be one of the factors that drive the clinical trial supply and logistics market for pharma. Rising need for cold chain logistics will increase demand for new packaging and monitoring technologies that offer lower-cost solutions, including reusable packaging and phase change materials that allow cooling for more-specific temperature ranges.

The lead analyst of the report commented "Emerging markets offer many benefits for companies looking to conduct clinical trials, including large patient population and lower trial costs. However, these also offer unique challenges in terms of clinical trial logistics. In many of these markets, the infrastructure connecting second and third tier cities is not as developed as that connecting major cities - these destinations are harder to reach, causing delays in distribution of trial materials, possible resulting in product spoilage.

Additionally, passing through or conducting trials at multiple sites within these regions results in having to comply with varying regulatory and import/export standards. Cold chain integrity also varies within these markets, with few distributors offering a complete cold chain network throughout emerging markets. However, Visiongain predicts that improvements will be made in all these areas in the coming decade, simplifying clinical trial logistics in emerging markets and further increasing their appeal as trial destinations."

Leading companies featured in the report include ADAllen Pharma, Almac Group, Amatsigroup, Biocair International Limited, Catalent, DHL, Durbin PLC, FedEx, Fisher Clinical Services, Marken. Movianto, Packaging Coordinators Inc. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever